At a glance
- Originator Tanabe Seiyaku
- Class Antineoplastics
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Jun 2000 New profile
- 01 Jun 2000 Preclinical development for Cancer in Japan (Unknown route)